6978 — Immunotech Biopharm Income Statement
0.000.00%
Last trade - 00:00
- HK$1.67bn
- HK$1.97bn
2019 December 31st | 2020 December 31st | 2021 December 31st | 2022 December 31st | 2023 December 31st | |
---|---|---|---|---|---|
Period Length: | 12 M | 12 M | 12 M | 12 M | 12 M |
Source: | PROSPECTUS | ARS | ARS | ARS | ARS |
Standards: | IFRS | IFRS | IFRS | IFRS | IFRS |
Status: | Final | Final | Final | Final | Final |
Revenue | |||||
Total Revenue | 0 | 0 | 0 | 0 | 0 |
Selling / General / Administrative Expenses | |||||
Research And Development | |||||
Depreciation and Amortization | |||||
Unusual Expense / Income | |||||
Other Operating Expenses | |||||
Total Operating Expenses | 99.6 | 436 | 351 | 301 | 326 |
Operating Profit | -99.6 | -436 | -351 | -301 | -326 |
Total Net Non Operating Interest Income / Expense | |||||
Other Net Non Operating Costs | |||||
Net Income Before Taxes | -109 | -439 | -355 | -321 | -335 |
Provision for Income Taxes | |||||
Net Income After Taxes | -109 | -439 | -355 | -321 | -335 |
Minority Interest | |||||
Net Income Before Extraordinary Items | |||||
Net Income | -109 | -439 | -354 | -318 | -335 |
Income Available to Common Shareholders Excluding Extraordinary Items | |||||
Income Available to Common Shareholders Including Extraordinary Items | |||||
Diluted Net Income | -109 | -439 | -354 | -318 | -335 |
Diluted Weighted Average Shares | |||||
Basic EPS Including Extraordinary Items | |||||
Diluted EPS Including Extraordinary Items | |||||
Diluted EPS Excluding Extraordinary Items | |||||
Normalised Income Before Taxes | |||||
Normalised Income After Taxes | |||||
Normalised Income Available to Common Shareholders | |||||
Diluted Normalised EPS | -0.212 | -0.905 | -0.691 | -0.616 | -0.651 |